Jonathan Paul M Mochel

DVM, MSc, PhD, Diplomate ECVPT

Dr. Mochel obtained his Veterinary Medical Degree from the National Veterinary School of Toulouse. In 2007, he completed his Doctorate studying Neurosciences in collaboration with the College de France (Paris), and received the Silver Medal from the National Veterinary School of Alfort for his work. 

During his veterinary undergraduate studies Dr. Mochel also obtained a Masters in Pharmacology and Pharmacokinetics (2006) from the University of Toulouse. Following a Medical Internship in Veterinary Medicine and Surgery at Maisons-Alfort (2006-2008), he also got a Master of Science (MS) in Pharmacology and Pharmacokinetics from the University of Toulouse. He then pursued a 4-year Specialization program in Pharmacology and Toxicology (European Board) and earned his title of European Specialist in Veterinary Pharmacology and Toxicology. 

Dr. Mochel did his Ph.D at Leiden University under the supervision of Pr. Meindert Danhof, whose focus was on the modeling of the dynamics of the renin-angiotensin aldosterone system (RAAS) in dogs. 

In 2012, he co-founded the Animal Health Modeling & Simulation (AHM&S) Society, together with Pr. Johan Gabrielsson (University of Agricultural Sciences, Uppsala, Sweden), and Pr. Jim Riviere (Kansas State University, USA), which aims at promoting the development, application, and dissemination of Modeling and Simulation techniques in the field of Veterinary Sciences (http://www.ahmss.com/). 

Since joining Novartis Pharmaceuticals in 2013, he had been working as a Senior Pharmacology Modeler in the Modeling and Simulation (M&S) group formed by Dr. Donald Stanski. He thereafter operated as a Quantitative Pharmacology Leader in the Research M&S department of Dr. Thierry Lave at Roche. 

Dr. Mochel is currently an Associate Professor in the Department of Biomedical Sciences at Iowa State University and the Chair of the Education and Residency Committee of the European College of Pharmacology and Toxicology (http://www.ecvpt.org/).

His research, which falls under the scope of the One Health initiative, pertains to the analysis of clinical data obtained from spontaneous animal models of human diseases to bridge the knowledge gap between experimental (i.e rodent) models and patients.

Education & Certifications  
  • OTH, Veterinary Medicine Degree (DEFV), 2006, National Veterinary School of Toulouse, Toulouse
  • MS, Pharmacology, 2006, Paul Sabatier University, Toulouse
  • DVM, Veterinary Medicine, 2007, Alfort Veterinary School, Paris 12 Val de Marne University, Maisons-Alfort
  • MS, Pharmacology/Pharmacokinetics, 2009, Paul Sabatier University, Toulouse
  • Resident, Veterinary Pharmacology and Toxicology, 2013, European College of Veterinary Pharmacology and Toxicology, Basel​
  • PhD, Pharmacology, 2015, Leiden University, Leiden
Teaching  

  • 2016-Present                       Associate Professor (Presidential High-Impact), Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA

  • 2015-2016                          Quantitative Systems Pharmacology Leader, Roche Innovation Center, Pharma Research and Early Development, Basel

  • 2013-2015                          Senior Pharmacology Modeler, Department of Modeling and Simulation, Novartis, Basel

  • 2011-2013                          Resident in Veterinary Pharmacology and Toxicology, Novartis, St Johann Campus, Pharmacology Modeling and Simulation, Basel

  • 2009-2013                          Resident in Veterinary Pharmacology and Toxicology, Novartis, Centre de Recherche Sante Animale, DMPK and Safety, Saint-Aubin

  • 2007-2008                          Chief Intern, Veterinary Internal Medicine and Surgery, Small Animal Internal Medicine and Surgery, Alfort Veterinary School, Maisons-Alfort

  • 2004-2006                          Teaching Assistant, Department of Physiology and Therapeutics, National Veterinary School of Toulouse, Toulouse
Research Focus & Interests  
  • Clinical Pharmacology
  • Pharmacokinetics and Pharmacodynamic Modeling
  • Cardiovascular Research
  • Translational Medicine (One Health)
Honors & Awards  
  • Valedictorian, Veterinary Medicine Graduate Class, National Veterinary School of Toulouse (2011)
  • Member, European Association for Veterinary Pharmacology and Toxicology (2015)
  • Member, European Federation for Pharmaceutical Sciences, Network on Veterinary Medicines (2015)
  • Fellow, American Academy of Veterinary Pharmacology and Therapeutics (2016)
  • Member, International Society of Pharmacometrics (2017)
  • Member, American Association of Pharmaceutical Scientists (2017)
Memberships  
  1. Co-Founder and Secretary, Animal Health Modeling and Simulation Society
  2. Member, European Association for Veterinary Pharmacology and Toxicology
  3. Member, European Federation for Pharmaceutical Sciences, Network on Veterinary Medicines
  4. Fellow, American Academy of Veterinary Pharmacology and Therapeutics
  5. Member, International Society of Pharmacometrics
  6. Member, American Association of Pharmaceutical Scientists
  7. Member, American Gastroenterology Association
Selected Publications  

NCBI Library

1. Bieth B, Bornkamp B, Toutain C, Garcia R, Mochel JP. Multiple comparison procedure and modeling: a versatile tool for evaluating dose-response relationships in veterinary pharmacology - a case study with furosemide. J Vet Pharmacol Ther. 2016 Dec;39(6):539-546. doi: 10.1111/jvp.12313. PubMed [citation] PMID: 27166146

2. Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. CPT Pharmacometrics Syst Pharmacol. 2016 Oct 22. doi: 10.1002/psp4.12141. [Epub ahead of print] PubMed [citation] PMID: 27770596

3. Lin Z, Gehring R, Mochel JP, Lavé T, Riviere JE. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. J Vet Pharmacol Ther. 2016 Oct;39(5):421-38. doi: 10.1111/jvp.12311. Review. PubMed [citation] PMID: 27086878

4. Dencker L, Hellmann K, Mochel JP, Senel S, Linden Hans, Vendrig D, Schmerold I Position Paper: EUFEPS Network on Veterinary Medicines Initiative. Eur J Pharm Sci. 2016 Aug 25; 91:I-VII.

5. Riviere JE, Gabrielsson J, Fink M, Mochel J. Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. J Vet Pharmacol Ther. 2016 Jun;39(3):213-23. doi: 10.1111/jvp.12278. Review. PubMed [citation] PMID: 26592724

6. Mochel JP, Fink M, Peyrou M, Soubret A, Giraudel JM, Danhof M. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with  Benazepril in Dogs. Pharm Res. 2015 Jun;32(6):1931-46. doi: 10.1007/s11095-014-1587-9. PubMed [citation] PMID: 25446774

7. Mochel JP, Danhof M. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? Rev Physiol Biochem Pharmacol. 2015;169:43-69. doi: 10.1007/112_2015_27. Review. PubMed [citation] PMID: 26428686

8. Mochel JP, Fink M, Bon C, Peyrou M, Bieth B, Desevaux C, Deurinck M, Giraudel JM, Danhof M. Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs. Chronobiol Int. 2014 Jun;31(5):715-30. doi: 10.3109/07420528.2014.897711. PubMed [citation] PMID: 24654920

9. Mochel JP, Fink M, Peyrou M, Desevaux C, Deurinck M, Giraudel JM, Danhof M. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology. Chronobiol Int. 2013 Nov;30(9):1144-59. doi: 10.3109/07420528.2013.807275. PubMed [citation] PMID: 23931032

10. Fink M, Letellier I, Peyrou M, Mochel JP, Jung M, King JN, Gruet P, Giraudel JM. Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis. Res Vet Sci. 2013 Oct;95(2):580-7. doi: 10.1016/j.rvsc.2013.04.021. PubMed [citation] PMID: 23726662

11. Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J. Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print] PubMed [citation] PMID: 23713757

12. Mochel JP, Peyrou M, Fink M, Strehlau G, Mohamed R, Giraudel JM, Ploeger B, Danhof M. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80. doi: 10.1111/j.1365-2885.2012.01406.x. PubMed [citation] PMID: 22568394

13. Mochel JP, Fink M. Response to letter from Atkins et al. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs J Vet Pharmacol Ther. 2012 Sept 11; 35:516-518

 

Abstracts and Conferences Papers

1. Mochel J, Danhof M. Pharmacodynamics of the renin-angiotensin aldosterone system and blood pressure in relation to food intake in dogs. 25th Population Approach Group in Europe (PAGE) Meeting, Lisbon (2016).

2. Mochel J. Chronopharmacology of the renin-angiotensin network in dogs. The value of model-based approaches: some ‘food for thought’. International Seminar Programme on Drug Innovation, Utrecht (2016).

3. Mochel J, Seewald W, Danhof M. Pharmacokinetics of the angiotensin receptor-neprilysin inhibitor LCZ696 in furosemide-treated dogs. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

4. Mochel J, Peyrou M, Giraudel J, Danhof M. First-in-class angiotensin receptor-neprilysin inhibitor LCZ696 markedly influences the dynamics of circulating cGMP and biomarkers of the renin-angiotensin aldosterone system in dogs. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

5. Mochel J. Chronopharmacology of the renin-angiotensin aldosterone system in dogs: the value of pharmacokinetic/pharmacodynamic modeling. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

6. Bieth B, Bornkamp B, Toutain C, Garcia R, Mochel J. Effect of furosemide on diuresis and renin-angiotensin aldosterone activation in dogs: a model

7. Pelligand L, Mochel J. Monte Carlo simulations and their application in veterinary medicine. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

8. Pelligand L, Renard D, Soubret A, King JN, Elliot J, Mochel J. Modeling of pharmacokinetic data using nonlinear mixed-effects: a paradigm shift in veterinary pharmacology. A case study with the nonsteroidal antiinflammatory robenacoxib in cats. 24th Population Approach Group in Europe (PAGE) Meeting, Hersonissos (2015).

 9. Mochel J, Burkey B, Fink M, Garcia R, Peyrou M, Giraudel J, Renard D, Danhof M. First-in-class angiotensin receptor neprilysin inhibitor LCZ696 modulates the dynamics of the renin cascade and natriuretic peptides system with significant reduction of aldosterone exposure. 63rd Annual Scientific Session of the American College of Cardiology, Washington (2014).

10. Mochel J, Renard D, Fink M, Danhof M. Daily variations of renin, urinary electrolytes and blood pressure are driven by food intake in dogs. 7th  Symposium on Pharmacokinetics, Pharmacodynamics and Systems Pharmacology, Noordwijkerhout (2014).

11. Fink M, Mochel J, Gabrielsson J, Collard W, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J. Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences. 22nd Population Approach Group in Europe (PAGE) Meeting, Glasgow (2013).

12. Mochel J, Fink M, Peyrou M, Desevaux C, Deurinck M, Danhof M. Chronobiology of the renin-angiotensin-aldosterone system in Dogs: relation to blood pressure and renal physiology. 22nd Population Approach Group in Europe (PAGE) Meeting, Glasgow (2013).

13. Mochel J. Tuning in to body’s rhythms to adapt dosing schedules. International Cardiology Advisory Board Meeting, Zurich (2013) based dose-response approach. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

14. Pelligand L, Soubret A, King JN, Elliot J, Mochel J. Simultaneous intravenous and subcutaneous population modelling of robenacoxib disposition kinetics in cats. 13th European Association for Veterinary Pharmacology and Toxicology Congress, Nantes (2015).

15. Mochel J, Bornkamp B, Bieth B. Evaluating the dose-response relationship of furosemide on diuresis and RAAS activation in dogs combining multiple comparisons and modeling techniques. 24th Population Approach Group in Europe (PAGE) Meeting, Hersonissos (2015).

16. Mochel J, Fink M, Peyrou M, Giraudel J, Danhof M. Using nonlinear mixed effects modeling to characterize the pharmacokinetics and pharmacodynamics of benazepril in dogs. 21st Population Approach Group in Europe (PAGE) Meeting, Venice (2012).

17. Mochel J, Fink M, Peyrou M, Desevaux, Deurinck M, Danhof M. Capturing the diurnal changes in renin activity and blood pressure to streamline drug therapy of RAAS-related disorders in dogs. 12h European Association for Veterinary Pharmacology and Toxicology Congress, Noordwijkerhout (2012).

18. Mochel J, Fink M, Peyrou M, Giraudel J, Danhof M. Population PK/PD modeling of benazepril-induced RAAS inhibition using nonlinear mixed effects. 12h European Association for Veterinary Pharmacology and Toxicology Congress, Noordwijkerhout (2012).

19. Mochel J, Fink M, Peyrou M, Giraudel J, Stanski D, Danhof M. Modeling and Simulation: a comprehensive tool to streamline drug development. 12h European Association for Veterinary Pharmacology and Toxicology Congress, Noordwijkerhout (2012).

20. Mochel J, Strehlau G, Mohamed R, Peyrou M. Dynamics of the reninangiotensin-aldosterone system (RAAS) after oral administration of benazepril in dogs. American College of Internal Medicine Forum, Denver (2011).